Are More Pharma cGMP Whistleblower Cases on the Way? Experts Think So
November 17, 2010
Pharmaceutical manufacturers are becoming increasingly aware that serious manufacturing deficiencies might subject them to False Claims Act liability. In turn, the industry is making strides to fully understand cGMPs and the reach of the federal False Claims Act. For example, PharmaManufacturing.com spotlighted this concern and directed the industry to Nolan Auerbach partner Ken Nolan, for his “excellent checklist” on cGMP violations.